Add to ORKGGoal: To better understand drug resistance and sensitivity in patients with late stage (Stage III & IV) cancers that are receiving standard of care molecularly targeted therapies through next generation sequencing (NGS) of biopsy and blood samples collected longitudinally (diagnosis-- treatment--progression).https://knowledgeconnection.mainehealth.org/lambrew-retreat-2021/1053/thumbnail.jp
The necessary infrastructure to carry out genomics-driven oncology is now widely available and has r...
Background: Despite increasing evidence of benefit supporting CGP in personalizing cancer therapy, i...
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data alo...
Goal: To better understand drug resistance and sensitivity in patients with late stage (Stage III & ...
PURPOSE: The Maine Cancer Genomics Initiative (MCGI) aimed to overcome patient- and provider-level b...
Mission: To provide normal and diseased annotated human biospecimens to the research community that ...
In recent decades, extensive resources have been invested to develop cellular, molecular and genomic...
Abstract Background Research suggests that multidisciplinary genomic tumor boards (MGTB) can inform ...
Background: Comprehensive genomic profiling (CGP) enables physicians to recommend advanced cancer tr...
According to the National Cancer Institute, the lack of standardized, high-quality biospecimens is o...
Context.— Genomic sequencing for cancer is offered by commercial for-profit laboratories, independen...
Introduction: The rapid evolution of precision medicine treatment options in cancer care has warrant...
PURPOSE: The cancer research community is constantly evolving to better understand tumor biology, di...
The Global Cancer Genomics Consortium (GCGC) is a cohesive network of oncologists, cancer biologists...
MLCC has two primary goals: 1. Engage and educate about evidence based lung cancer prevention and sc...
The necessary infrastructure to carry out genomics-driven oncology is now widely available and has r...
Background: Despite increasing evidence of benefit supporting CGP in personalizing cancer therapy, i...
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data alo...
Goal: To better understand drug resistance and sensitivity in patients with late stage (Stage III & ...
PURPOSE: The Maine Cancer Genomics Initiative (MCGI) aimed to overcome patient- and provider-level b...
Mission: To provide normal and diseased annotated human biospecimens to the research community that ...
In recent decades, extensive resources have been invested to develop cellular, molecular and genomic...
Abstract Background Research suggests that multidisciplinary genomic tumor boards (MGTB) can inform ...
Background: Comprehensive genomic profiling (CGP) enables physicians to recommend advanced cancer tr...
According to the National Cancer Institute, the lack of standardized, high-quality biospecimens is o...
Context.— Genomic sequencing for cancer is offered by commercial for-profit laboratories, independen...
Introduction: The rapid evolution of precision medicine treatment options in cancer care has warrant...
PURPOSE: The cancer research community is constantly evolving to better understand tumor biology, di...
The Global Cancer Genomics Consortium (GCGC) is a cohesive network of oncologists, cancer biologists...
MLCC has two primary goals: 1. Engage and educate about evidence based lung cancer prevention and sc...
The necessary infrastructure to carry out genomics-driven oncology is now widely available and has r...
Background: Despite increasing evidence of benefit supporting CGP in personalizing cancer therapy, i...
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data alo...